Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET/CT
J Duell, F Krummenast, A Schirbel… - Journal of Nuclear …, 2021 - Soc Nuclear Med
PET/CT with 18F-FDG is an integral component in the primary staging of most lymphomas.
However, its utility is limited in marginal-zone lymphoma (MZL) because of inconsistent 18F …
However, its utility is limited in marginal-zone lymphoma (MZL) because of inconsistent 18F …
The use of the macrocyclic chelator DOTA in radiochemical separations
Radiometals play an important role in the diagnosis of physiological processes in vivo by
means of imaging technologies, but also increasingly contribute to the treatment of diseases …
means of imaging technologies, but also increasingly contribute to the treatment of diseases …
Cell tracking in cancer immunotherapy
J Perrin, M Capitao, M Mougin-Degraef… - Frontiers in …, 2020 - frontiersin.org
The impressive development of cancer immunotherapy in the last few years originates from
a more precise understanding of control mechanisms in the immune system leading to the …
a more precise understanding of control mechanisms in the immune system leading to the …
Clinical advances and perspectives in targeted radionuclide therapy
N Lepareur, B Ramée, M Mougin-Degraef… - Pharmaceutics, 2023 - mdpi.com
Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …
CXCR4-directed imaging in solid tumors
Despite histological evidence in various solid tumor entities, available experience with
CXCR4-directed diagnostics and endoradiotherapy mainly focuses on hematologic …
CXCR4-directed diagnostics and endoradiotherapy mainly focuses on hematologic …
In vivo targeting of CXCR4—new horizons
M Schottelius, K Herrmann, C Lapa - Cancers, 2021 - mdpi.com
Simple Summary Beyond its pre-eminent role in the context of tumor cell growth as well as
metastasis, the CXC motif chemokine receptor 4 (CXCR4) is a key player in the …
metastasis, the CXC motif chemokine receptor 4 (CXCR4) is a key player in the …
[HTML][HTML] The theranostic promise for Neuroendocrine Tumors in the late 2010s-Where do we stand, where do we go?
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept
of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors …
of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors …
[HTML][HTML] A new class of PentixaFor-and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
T Osl, A Schmidt, M Schwaiger, M Schottelius… - Theranostics, 2020 - ncbi.nlm.nih.gov
Non-invasive PET imaging of CXCR4 expression in cancer and inflammation as well as
CXCR4-targeted radioligand therapy (RLT) have recently found their way into clinical …
CXCR4-targeted radioligand therapy (RLT) have recently found their way into clinical …
Theranostics: leveraging molecular imaging and therapy to impact patient management and secure the future of nuclear medicine
Nuclear medicine is experiencing a renaissance, with US Food and Drug Administration
approval recently being obtained for theranostic agents and a wide variety of such agents …
approval recently being obtained for theranostic agents and a wide variety of such agents …
Radionuclide imaging and therapy directed towards the tumor microenvironment: A multi-cancer approach for personalized medicine
CD van der Heide, SU Dalm - European Journal of Nuclear Medicine and …, 2022 - Springer
Targeted radionuclide theranostics is becoming more and more prominent in clinical
oncology. Currently, most nuclear medicine compounds researched for cancer theranostics …
oncology. Currently, most nuclear medicine compounds researched for cancer theranostics …